ArticleMolecular medicine reports2021
circ‑0000212 promotes cell proliferation of colorectal cancer by sponging miR‑491 and modulating FOXP4 expression.
Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Decision tree-based machine learning methods for identifying colorectal cancer-associated microRNA signatures and their regulatory networks.Scientific reports · 2025Article
- FOXP4 Is a Direct YAP1 Target That Promotes Gastric Cancer Stemness and Drives Metastasis.Cancer research · 2024Article
- Regulation of Cervical Cancer Development by a Novel Circ_0000212/miR-1236-3p/GREM1 ceRNA Crosstalk.Molecular biotechnology · 2023Article
- Biological functions, mechanisms, and clinical significance of circular RNA in colorectal cancer.Frontiers in oncology · 2023Review
- Knockdown of hsa_circ_0043691 restrains the progression of gastric cancer by decoying miR-1294 to target pre-leukemia transcription factor 3.Journal of clinical laboratory analysis · 2022Article
- Downregulation of Circ-PITHD1 Suppressed Colorectal Cancer via Glycolysis Inhibition through miR-590-5p/HK2 Axis.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Low Expression of miR-491-3p Is Correlated with Lymph Node Metastasis in Gastric Cancer.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- LncRNA FOXP4-AS1 Promotes the Progression of Esophageal Squamous Cell Carcinoma by Interacting With MLL2/H3K4me3 to Upregulate FOXP4.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a lethal and common malignancy worldwide. Non‑coding (nc)RNAs have been shown to modulate tumor progression in several types of cancer. The present study aimed to investigate the role of hsa_circ_0000212 in CRC, as a sponge of microRNA (miR)‑491. The expression levels of miR‑491 and forkhead box P4 (FOXP4) were analyzed using data from The Cancer Genome Atlas. The association between miR‑491 and FOXP4 and the clinicopathological characteristics were also analyzed. A novel circular (circ)RNA, hsa_circ_0000212, was found to sponge miR‑491 based on bioinformatics analysis. The potential binding site between miR‑491 and FOXP4 or circ‑0000212 was validated using luciferase and RNA immunoprecipitation assays. The expression levels and distribution of circ‑0000212 was also determined. Cell Counting Kit‑8 and colony formation assays were performed to determine the role of miR‑491 or circ‑0000212 on the proliferation of the CRC cells. Decreased miR‑491 or increased FOXP4 expression levels were associated with the pathological stage in patients with CRC. In addition, miR‑491 inhibited cell proliferation by targeting FOXP4. circ‑0000212 was increased in CRC tissues and was predominantly localized in the cytoplasm. Furthermore, circ‑0000212 augmented viability of the CRC cells by sponging miR‑491 and modulating FOXP4. In conclusion, circ‑0000212 may serve as a novel tumor‑promoter and drug target in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.